Package Leaflet: Information for the Patient
Spedra 200 mg Tablets
avanafil
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the Package Leaflet
Spedra contains the active substance avanafil. It belongs to a group of medicines called phosphodiesterase type 5 inhibitors (PDE5). Spedra is a treatment for adult men who suffer from erectile dysfunction (also known as impotence). This occurs when a man cannot achieve or maintain a firm erection for sexual intercourse.
Spedra works by helping the blood vessels in your penis to relax. This increases blood flow to the penis, helping it to stay hard and erect after sexual stimulation. Spedra does not cure your condition.
It is essential that you know Spedra only works if you receive sexual stimulation. You and your partner should engage in foreplay before sex, just as you would if you were not taking a medication to help you.
Spedra will not help you if you do not suffer from erectile dysfunction. Spedra is not indicated for use in women.
Do not take Spedra:
Do not take Spedra if you are in any of the above situations. If you are unsure, consult your doctor or pharmacist before taking Spedra.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Spedra:
If you are in any of the above situations, consult your doctor or pharmacist before starting to take Spedra. In case of doubt, consult your doctor or pharmacist.
Vision or hearing problems
Some men who take medicines like Spedra have experienced vision and hearing problems; see "Serious side effects" in section 4 for detailed information. It is not known whether these problems are directly related to Spedra, other conditions you may have, or a combination of factors.
If you experience sudden loss of vision or your vision is distorted or blurred while taking Spedra, stop taking Spedra and contact your doctor immediately.
Children and adolescents
Spedra is not indicated for use in children or adolescents under 18 years of age.
Using Spedra with other medicines
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, as Spedra may affect the activity of some medicines. Additionally, other medicines may affect the activity of Spedra.
In particular, inform your doctor and do not take Spedra if you are taking medicines with "nitrites" for chest pain (angina), such as amyl nitrite or glyceryl trinitrate. It has been shown that Spedra enhances the effects of these medicines and significantly lowers blood pressure. Also, do not take Spedra if you are taking medicines for HIV or AIDS, such as ritonavir, indinavir, saquinavir, nelfinavir, or atazanavir, or if you are taking medicines for fungal infections, such as ketoconazole, itraconazole, or voriconazole, or certain antibiotics for bacterial infections, such as clarithromycin or telithromycin (see the beginning of section 2, "Do not take Spedra").
Tell your doctor or pharmacist if you are taking any of the following medicines:
Do not use Spedra with other treatments for erectile dysfunction, such as sildenafil, tadalafil, or vardenafil.
If you are in any of the above situations, consult your doctor or pharmacist before taking Spedra. In case of doubt, consult your doctor or pharmacist.
Using Spedra with drinks and alcohol
Grapefruit juice may increase exposure to the medication and should be avoided within 24 hours before taking Spedra.
Consuming alcohol at the same time as Spedra may accelerate heart rate and lower blood pressure. You may feel dizzy (especially when standing), experience headache, or feel your heartbeat in your chest (palpitations). Alcohol consumption may decrease your ability to achieve an erection.
Fertility
No effects on sperm movement or structure have been observed after single oral doses of 200 mg of avanafil in healthy volunteers.
Repeated oral administration of avanafil 100 mg for a period of 26 weeks in healthy volunteers and in adult men with mild erectile dysfunction was not associated with any adverse effects on sperm concentration, count, motility, or morphology.
Driving and using machines
Spedra may cause dizziness or affect your vision. If this occurs, do not drive, ride a bicycle, or use tools or machines.
Follow the instructions for administration of this medication indicated by your doctor.
In case of doubt, consult your doctor or pharmacist.
The recommended dose is one 100 mg tablet as needed. You should not take Spedra more than once a day. Your doctor may prescribe a 200 mg tablet if they consider the 100 mg dose too weak for you or a 50 mg tablet if they consider the 100 mg dose too strong. Additionally, it may be necessary to adjust the dose if Spedra is used with certain medicines. If you are taking a medicine such as erythromycin, amprenavir, aprepitant, diltiazem, fluconazole, fosamprenavir, or verapamil ("moderate CYP3A4 inhibitors"), the maximum recommended dose of Spedra is one 100 mg tablet, with an interval of at least 2 days between doses.
You should take Spedra approximately 15 to 30 minutes before sexual intercourse. Remember that Spedra will only help you achieve an erection if you receive sexual stimulation.
Spedra can be taken with or without food. If taken with food, it may take longer to act.
If you take more Spedra than you should
If you take too much Spedra, inform your doctor immediately. You may experience more side effects than usual, and they may be worse.
If you have any further questions on the use of this medication, ask your doctor or pharmacist.
Like all medicines, Spedra can cause side effects, although not everybody gets them.
Serious side effects
Stop taking Spedra and consult a doctor immediately if you notice any of the following serious side effects; you may need urgent medical treatment:
Stop taking Spedra and consult a doctor immediately if you notice any of the above serious side effects.
Other side effects include:
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Reporting side effects
If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this package leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting side effects, you can help provide more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date stated on the blister and carton after "EXP": The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Spedra
Appearance of Spedra and Package Contents
Spedra is a light yellow oval tablet with "100" engraved on one side. The tablets are presented in single-dose precut blisters containing 2x1, 4x1, 8x1, or 12x1 tablets.
Only some package sizes may be marketed in your country.
Marketing authorization holder:
MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A., 1, Avenue de la Gare, L-1611 Luxembourg, Luxembourg
Manufacturer:
Menarini - Von Heyden GmbH
Leipziger Straße 7-13
01097 Dresden, Germany.
or
Sanofi Winthrop Industrie
1, rue de la Vierge
Ambares et Lagrave
33565 Carbon-Blanc-Cedex
France
You can request more information about this medication by contacting the local representative of the marketing authorization holder.
België/Belgique/BelgienMenarini Benelux NV/SA Tel: + 32 (0)2 721 4545 | Lietuva UAB “BERLIN-CHEMIE MENARINI BALTIC” Tel: +370 52 691 947 |
Luxembourg/LuxemburgMenarini Benelux NV/SA Tel: + 32 (0)2 721 4545 | |
Ceská republika Berlin-Chemie/A.Menarini Ceska republika s.r.o. Tel: +420 267 199 333 | Magyarország Berlin-Chemie/A. Menarini Kft. Tel.: +36 23501301 |
DanmarkPharmaprim AB Tlf: +46 8355933 | Malta Menarini International Operations Luxembourg S.A. Tel: +352 264976 |
Deutschland Berlin-Chemie AG Tel: +49 (0) 30 67070 | Nederland Menarini Benelux NV/SA Tel: +32 (0)2 721 4545 |
Eesti OÜ Berlin-Chemie Menarini Eesti Tel: +372 667 5001 | NorgePharmaprim AB Tlf: +46 8355933 |
Ελλάδα MENARINI HELLAS AE Τηλ: +30 210 8316111-13 | Österreich
|
España Laboratorios Menarini S.A. Tel: +34-93 462 88 00 | Polska Berlin-Chemie/Menarini Polska Sp. z o.o. Tel.: +48 22 566 21 00 |
France MENARINI France Tél: +33 (0)1 45 60 77 20 | Portugal
Tel: +351 210 935 500 |
Hrvatska Berlin-Chemie Menarini Hrvatska d.o.o. Tel: + 385 1 4821 361 | România Berlin-Chemie A. Menarini S.R.L. Tel: +40 21 232 34 32 |
Ireland
Tel: +353 1 284 6744 | Slovenija Berlin-Chemie / A. Menarini Distribution Ljubljana d.o.o. Tel: +386 01 300 2160 |
ÍslandPharmaprim AB Sími: +46 8355933 | Slovenská republika Berlin-Chemie / A. Menarini Distribution Slovakia s.r.o Tel: +421 2 544 30 730 |
Italia
s.r.l. Tel: +39-055 56801 | Suomi/Finland Berlin-Chemie/A.Menarini Suomi OY Puh/Tel: +358 403 000 760 |
Κύπρος MENARINI HELLAS AE Τηλ: +30 210 8316111-13 | SverigePharmaprim AB Tel: +46 8355933 |
Latvija SIA Berlin-Chemie/Menarini Baltic Tel: +371 67103210 | United Kingdom (Northern Ireland)
|
Date of the Last Revision of this Leaflet
Detailed information on this medication is available on the European Medicines Agency website: http://www.ema.europa.eu.